Ignite Creation Date:
2024-05-06 @ 2:51 PM
Last Modification Date:
2024-10-26 @ 1:38 PM
Study NCT ID:
NCT04443309
Status:
RECRUITING
Last Update Posted:
2023-03-29
First Post:
2020-06-21
Brief Title:
Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC
Sponsor:
Peking Union Medical College Hospital
Organization:
Peking Union Medical College Hospital
Organization Data
Organization:
Peking Union Medical College Hospital
Class:
OTHER
Study ID:
JS-2286
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Peking Union Medical College Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Jiangsu HengRui Medicine Co Ltd | INDUSTRY |